Skip to main content
. 2020 May 27;10:831. doi: 10.3389/fonc.2020.00831

Table 2.

Biochemical biomarkers in use for PanNEN diagnosis, prognosis, and treatment monitoring.

Biochemical markers Source Level Sens. (%) Spec. (%) Combinations improving sens./spec. Clinical use References
Non–specific Chromogranin A CHGA Serum 63–14.750 ug/l 60–83 72–85 NSE; PP For diagnosis and follow up in GEP-NENs and treatment monitoring (20, 21) (22, 23)
Neuron-specific enolase NSE Plasma 5–92 ug/l 33 73 CHGA For diagnosis and follow up in GEP-NENs and treatment monitoring (20, 21) (22, 23)
Pancreatic-Polipetide PP Plasma 480–780 pg/ml 31-63 67 CHGA For diagnosis and follow up in PanNENs (23)
Human Corionic Gonadotropin HCG Serum Increased na Na AFP; CHGA; PP; HCG Indicative of pancreatic origin (24)
Alpha Fetoprotein AFP Serum Increased na Na HCG; CHGA; PP Indicative of pancreatic origin and de-differentiation (25, 26)
Specific Gastrin GAS Serum ≥300 pg/mL 94 100 MEN-1; ZES Diagnostic for Gastrinoma of pancreatic origin (24, 27)
Insulin INS Serum/ Plasma ≥43 pmol/L 52 - 94 92−100 Whipple's triad Diagnostic for Insulinoma; suggesting for WD NETs. (28)
Glucagon GCG Plasma 500–1000 pg/mL High High - Diagnostic for Glucagonoma; suggesting for WD NETs; Indication for liver metastases (24)
Somatostatin SST Plasma Increased° na Low SSoma syndrome° Diagnostic for SSoma of pancreatic origin; (24)
Vasoactive Intestinal Peptide VIP Serum/Plasma 75−200 pg/dL na na Verner Morrison Diagnostic for ViPoma of pancreatic tail origin. (29)

PanNENs, Pancreatic Neuroendocrine Neoplasia; GEP-NENs, Gastro-Entero-Pancreatic Neoplasia; WD NETs, well differentiated tumors; Sens., sensibility; Spec., specificity. Diagnostic serum/plasma level in association with specific syndrome. °Somatostatin increase is very a-specific, increase SS level with SSoma syndrome is suggesting for GEP-NENs.